Filtered By:
Condition: Bleeding
Management: Health Insurance

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
CONCLUSIONS: These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.PMID:33733969 | DOI:10.1080/03007995.2021.1901223
Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research

Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
ConclusionsThese results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity and polypharmacy in a commercially-insured US population.
Source: Advances in Therapy - May 25, 2021 Category: Drugs & Pharmacology Source Type: research

Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research

Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies
Conclusions: This study provides further evidence of the safety of colonoscopy in routine practice with regard to delayed and non-GI AEs. Hospitalizations because of the investigated AEs were uncommon or rare for both screening and nonscreening colonoscopies.
Source: Gastrointestinal Endoscopy - February 15, 2013 Category: Gastroenterology Authors: Christian Stock, Peter Ihle, Andreas Sieg, Ingrid Schubert, Michael Hoffmeister, Hermann Brenner Tags: Clinical Endoscopy Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
CONCLUSIONS: Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs. PMID: 30472021 [PubMed - as supplied by publisher]
Source: Chest - November 22, 2018 Category: Respiratory Medicine Authors: Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH Tags: Chest Source Type: research

Long-Term Clinical Outcome of Drug-Eluting vs. Bare-Metal Stent Implantation After Percutaneous Coronary Intervention in End-Stage Renal Disease Patients on Hemodialysis 　- Nationwide Cohort Study in Taiwan.
CONCLUSIONS: In patients on chronic hemodialysis, implantation of DES did not have a better clinical outcome than BMS. PMID: 31019157 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 22, 2019 Category: Cardiology Authors: Chen ML, Wu JL, Chen MY, Hsieh TC Tags: Circ J Source Type: research

Effectiveness and Safety of Four Direct Oral Anticoagulants in Asians with Non-valvular Atrial Fibrillation.
CONCLUSIONS: In the largest real-world practice study among Asians with NVAF, four DOACs were associated with lower risks of thromboembolism and bleeding than warfarin. There was consistency even amongst high risk subgroups and whether standard dose or low dose regimes were compared. PMID: 31103697 [PubMed - as supplied by publisher]
Source: Chest - May 15, 2019 Category: Respiratory Medicine Authors: Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT, Chang SH, Lip GYH Tags: Chest Source Type: research

Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study.
CONCLUSION:  In the first study of a nationwide population cohort, we show that compliance with the simple ABC pathway is associated with improved clinically relevant outcomes of patients with AF. Given the high health care burden associated with AF, such a streamlined holistic approach to AF management should be implemented, to improve the care of such patients. PMID: 31266082 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2019 Category: Hematology Authors: Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Joung B, Lip GYH Tags: Thromb Haemost Source Type: research

Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea
ConclusionAspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia. Moreover, the benefits of the long-term use of aspirin in reducing the risks of MACCE were demonstrated. However, the decision of using aspirin for primary prevention must be carefully made on an individual basis, while estimating the benefit –risk balance of aspirin.
Source: Drugs and Aging - November 21, 2019 Category: Geriatrics Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation Patients with Concomitant Hyperthyroidism.
CONCLUSION: Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study. PMID: 32009154 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - February 2, 2020 Category: Endocrinology Authors: Chan YH, Wu LS, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF, Lip GYH Tags: J Clin Endocrinol Metab Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients. PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation
ConclusionsFor patients whose HAS-BLED scores increased to  ≥ 3, the continuation of OACs was associated with better clinical outcomes. An increased HAS-BLED score in anticoagulated AF patients may not be the only reason to withhold OACs, but reminds physicians to correct modifiable bleeding risk factors and follow up patients more closely.Graphical abstractAssociations between Continuation or Discontinuation of Oral Anticoagulants and Risks of Clinical Outcomes after HAS-BLED Scores IncreasedAF atrial fibrillation;aHR adjusted hazard ratio;ICH intra-cranial hemorrhage;OACs oral anticoagulants
Source: Clinical Research in Cardiology - March 11, 2021 Category: Cardiology Source Type: research